A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
Year: 2025
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Yanmin M. Zhao, Yi Luo, Jimin M. Shi, Shunqing Q. Wang, Caixia K. Wang, Erlie L. Jiang, Chen Liang, Xiaoyu Y. Zhu, Xuejun J. Zhang, Fankai K. Meng, Hua Jin, Yeqian Q. Zhao, Jian Yu, Xiaoyu Y. Lai, Lizhen Z. Liu, Huarui R. Fu, Yishan S. Ye, Congxiao X. Zhang, Tao Wang, Lifan F. Tu, Xunqiang Q. Wang, He Huang
Institutions: First Affiliated Hospital Zhejiang University, Zhejiang University, Guangzhou First People's Hospital, South China University of Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, University of Science and Technology of China, Anhui Provincial Hospital, Second Hospital of Hebei Medical University, Tongji Hospital, Huazhong University of Science and Technology, Nanfang Hospital, Southern Medical University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407953618